AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03944811 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: piezoelectric device
Description: crestal approach will be used to augment the maxillary sinus with simultaneous implant placement
Study NCT03944811 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Summers technique
Description: Summers technique
Study NCT02520141 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02520141 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Given IV
Study NCT03410602 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Full-mouth supragingival scaling
Description: Control group comprised of 15 patients who were treated with routine full-mouth supragingival scaling.
Study NCT03410602 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Full-mouth supragingival scaling
Description: Control group comprised of 15 patients who were treated with routine full-mouth supragingival scaling.
Study NCT03410602 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subgingival scaling
Description: Test group comprised of 15 patients who were treated with subgingival scaling only around all banded first molars.
Study NCT03410602 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Subgingival scaling
Description: Test group comprised of 15 patients who were treated with subgingival scaling only around all banded first molars.
Study NCT03410602 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subgingival irrigation
Description: Test group comprised of 15 patients who were treated with subgingival irrigation only around all banded first molars with 0.2% chlorhexidine gluconate solution (Trade name: HEXIDINE), an antiseptic - antiplaque agent.
Study NCT04352049 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preoxygenation
Study NCT01657214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR125844
Description: Pharmaceutical form:Concentrate for solution~Route of administration: intravenous
Study NCT03598140 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil Citrate
Description: Sildenafil 60mg once (Group 1) or daily for 2 weeks (Group 2)
Study NCT03598140 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo once (Group 1) or daily for 2 weeks (Group 2)
Study NCT02890511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Oral administration on day 1,8,15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed consent.
Study NCT00095394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan/HCTZ
Description: Tablets, Oral, Irbesartan 150mg/HCTZ 12.5 mg, Once daily, 7 weeks.
Study NCT00095394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan monotherapy
Description: Tablets, Oral, 150 mg, Once daily, 7 weeks.
Study NCT02217449 — intervention group
Intervention type: OTHER
Intervention: Prediction of histology
Study NCT01108263 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INTEGRA™ Flowable Matrix (Collagen)
Description: INTEGRA™ Flowable Wound Matrix is an advanced 3-D porous matrix comprised of granulated cross-linked bovine tendon collagen and glycosaminoglycan. It provides a scaffold for cellular invasion and capillary growth. The collagen and glycosaminoglycan mix is hydrated with saline and applied on the wound bed.
Study NCT01265940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib as add-on to vinflunine
Description: Patients will receive vinflunine standard regimen (intravenous infusion every three weeks) as specified per drug label plus additional pazopanib as daily oral medication. Doses of pazopanib will be escalated in 200 mg/d steps during phase I up to a maximum of 800 mg/d.~In Phase II the patients will be given pazopanib + vinflunine at maximum tolerated dose.
Study NCT01211067 — intervention group
Intervention type: PROCEDURE
Intervention: Lichtenstein hernioplasty
Description: * Mesh hernioplasty~* Ultrapro mesh (Ethicon, Johnson \& Johnson)
Study NCT00818636 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive writing (in addition to group therapy as usual).
Description: Participants in the expressive writing condition write about their feelings about an issue of their choosing three times, for at least 20 minutes each time, during a two week period.
Study NCT00818636 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Expressive writing (in addition to group therapy as usual).
Description: Participants in the expressive writing condition write about their feelings about an issue of their choosing three times, for at least 20 minutes each time, during a two week period.
Study NCT03869632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YL-13027
Description: Daily doses by oral administration on each day of each 28 day cycle. Starting dose is 60mg, with escalation to 360mg, and subsequent dose escalation using a modified Fibonacci algorithm.
Study NCT00474552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAM-315
Description: Multiple Ascending Doses of SAM-315 (treatment duration: 14 days): 0.2 mg; 0.5 mg; 1 mg; 2 mg;
Study NCT00648973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine 50 mg
Description: Three times daily: two diphenhydramine 25 mg capsules~Twice daily: one pseudoephedrine-matching placebo tablet
Study NCT00648973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine 25 mg
Description: Three times daily: one diphenhydramine 25 mg capsule and one diphenhydramine-matching placebo capsule~Twice daily: one pseudoephedrine-matching placebo tablet
Study NCT00648973 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pseudoephedrine 120 mg
Description: Three times daily: two diphenhydramine-matching placebo capsules~Twice daily: one pseudoephedrine 120 mg tablet
Study NCT04035473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HM30181 methanesulfonate monohydrate plus oral paclitaxel capsules
Description: HM30181 methanesulfonate monohydrate plus oral paclitaxel capsules~Oral paclitaxel capsules
Study NCT01834469 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: iv injection of ICG
Description: An iv injection will be performed for the ovarian cancer patient before the operation.
Study NCT00966849 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conditional Cash Transfer
Description: Households will receive bimonthly payments of US$18 plus US$4 per child under 18 years living in the house up to a maximum of 3 children i.e. transfers will vary from $22 to $30. Households will only be given the cash if they comply with the following conditions:~* An application for a birth certificate must be made for all children under 18 years in the household who do not already have a birth certificate, including all newborn children within 3 months of birth.~* All children under 5 years in the household must be up-to-date with vaccinations.~* All children under 5 years must attend a growth monitoring clinic twice per year.~* All children 6-17 years in the household attended school at least 90% of days in the last month.~* At least one adult from each household attended at least 2 of the 3 most recent parenting skills classes.
Study NCT00966849 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unconditional Cash Transfers
Description: Households will receive bimonthly payments of US$18 plus US$4 per child under 18 years living in the house up to a maximum of 3 children i.e. transfers will vary from $22 to $30. Households will not be required to comply with conditions in order to receive the cash.
Study NCT00966849 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Agricultural Package
Description: A standard agricultural package (e.g. seeds, fertiliser etc.) will be distributed in all study arms including the control arm as a gesture of goodwill to all those participating in the study.
Study NCT00966849 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Agricultural Package
Description: A standard agricultural package (e.g. seeds, fertiliser etc.) will be distributed in all study arms including the control arm as a gesture of goodwill to all those participating in the study.
Study NCT00966849 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parenting Skills Classes
Description: 2-3 parenting skills classes will be held annually in each study cluster.
Study NCT00966849 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Parenting Skills Classes
Description: 2-3 parenting skills classes will be held annually in each study cluster.
Study NCT04083599 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN1042
Description: Intravenous
Study NCT04083599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous
Study NCT04083599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Intravenous
Study NCT04083599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous
Study NCT00731289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triamcinolone
Description: one intraarticular injection of triamcinolone 1 ml (Volon A10®, 10mg triamcinolone acetonide, 10mg/ml)~antiinflammatory intervention
Study NCT00715078 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: sipuleucel-T
Description: Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF)
Study NCT00933309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: 25 mg tablets orally once a day
Study NCT00933309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avandamet
Description: Beginning dose 2 mg rosiglitazone with 500 mg metformin hydrochloride (2mg/500 mg) tablets taken orally once a day
Study NCT04083599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Intravenous
Study NCT04083599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenous
Study NCT04083599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Intravenous
Study NCT04083599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Intravenous
Study NCT04083599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Intravenous
Study NCT03232801 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness-based multicomponent intervention
Description: A group-based, multicomponent behavioral intervention rooted in mindfulness
Study NCT03232801 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: general health education group
Description: A general health and aging education group
Study NCT01751867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine at 15 mg/m2
Description: Decitabine will be given at a dose of 15 mg/m2 as a continuous intravenous infusion within a 3-hour intravenous infusion, repeated every 8 hours for 3 consecutive days.The total dose per day is 45 mg/m2; The total dose per course is 135 mg/m2. Cycles will be repeated every 6 weeks.
Study NCT01751867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine at 20 mg/m2
Description: Decitabine will be given at a dose of 20 mg/m2 as 1-hour IV infusion once daily on Days 1 through 5, of a 4-week treatment cycle.
Study NCT04137003 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rouge et Or Program
Description: It is a detailed, structured and precise training program. It is used from the third-month post ACL surgery to the sixth month.
Study NCT01783574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone
Study NCT01783574 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02029183 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bi level positive pressure ventilation
Description: Bi level positive pressure ventilation should be given for subject for 6 hours per night ，total 7 times.
Study NCT04137003 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CHU intervention guide
Description: From the third month to the sixth month, it outlines the progression to have in the training without precise information on exercises, parameter or frequency.
Study NCT04464512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: IV buprenorphine plus IV sufentanil treatment group.
Study NCT03349112 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 4% Lidocaine Spray
Description: 2% Viscous Lidocaine is applied to the nares as standard of care. In this intervention, 4% lidocaine spray is applied additionally.
Study NCT03349112 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 2% Viscous Lidocaine
Description: 2% Viscous Lidocaine is applied to the nares as standard of care. This intervention is considered as the control group.
Study NCT03349112 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: 2% Viscous Lidocaine
Description: 2% Viscous Lidocaine is applied to the nares as standard of care. This intervention is considered as the control group.
Study NCT02485301 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A)
Description: A single dose administrated intramuscular
Study NCT02485301 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A)
Description: A single dose administrated intramuscular
Study NCT02485301 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose administrated intramuscular
Study NCT00157950 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gardasil™
Description: Gardasil™ 3 dose regimen (Day 1, Month 2 and Month 6)
Study NCT00157950 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gardasil™ matching placebo 3 dose regimen (Day 1, Month 2 and Month 6)
Study NCT02029183 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bi-level positive airway pressure
Study NCT00269282 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Management Training
Description: Asthma education and self-monitoring strategies
Study NCT00269282 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Management Training
Description: Asthma education and self-monitoring strategies
Study NCT00269282 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Description: Motivational Interviewing (MI) is a promising interventional approach that uses a client-centered, non-directive approach for enhancing motivation to change health behaviors.
Study NCT03589950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anlotinib plus chemotherapy
Description: Anlotinib (12mg QD PO d1-14, 21 days per cycle), Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d/S-1 (80-120mg/day,depending on body surface area; days 1-28 in a 6-week cycle)
Study NCT02994953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Participants received avelumab intravenous (IV) infusion once a week on Day 1 and Day 15 of each cycle.
Study NCT02994953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M9241
Description: Participants received Subcutaneous (SC) injection of M9241 in escalating doses on Day 1 of each cycle.
Study NCT03589950 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d/S-1 (80-120mg/day,depending on body surface area; days 1-28 in a 6-week cycle)
Study NCT01529346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05089771
Description: A single dose of PF-05089771 1600 mg oral solution administered once to the subject on Day 1 postoperatively
Study NCT01529346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets for ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
Study NCT01529346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05089771
Description: A single dose of PF-05089771 450 mg oral solution administered once to the subject on Day 1 postoperatively
Study NCT01529346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05089771
Description: A single dose of PF-05089771 150 mg oral solution administered once to the subject on Day 1 postoperatively
Study NCT01529346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: 2 X 200 mg tablets of ibuprofen administered orally once to the subject on Day 1 postoperatively
Study NCT01529346 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo solution for PF-05089771: A single dose of Placebo solution administered once to the subject on Day 1 postoperatively
Study NCT01529346 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution for PF-05089771:A single dose of Placebo solution administered once to the subject on Day 1 postoperatively
Study NCT01529346 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets for Ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
Study NCT00386776 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer-based medical history
Description: The intervention is a computer-based medical interview, which contains 232 primary questions that are asked of all respondents, and over 6000 frames (questions, explanations, suggestions, recommendations, and words of encouragement) that are available for presentation as determined by the patient's responses and the branching logic of the program.
Study NCT01705899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Pancreatic Islets
Description: Pancreatic islet tissue suspended in 150 - 300 ml of phenol red-free CMRL-1066 Transplant Media supplemented with 4% (w/v) HSA and 16mM HEPES in a 600ml transfer pack. Heparin will be administered at 70 IU/kg recipient body weight. Administered by intra-portal vein infusion. To be administered once, however, if full graft function is not achieved, a second or third dose of Pancreatic Islets may be given within 18 months of the first transplant.
Study NCT01610947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab, Etanercept, Golimumab or infliximab
Description: Continuation of usual treatment with fixed intervals according to standard recommendations
Study NCT01610947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab, Etanercept, Golimumab or infliximab
Description: Progressive spacing of injections according to disease activity observed during follow-up and predefined protocol
Study NCT03454581 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: PBM was applied, three times a week for four consecutive weeks at 5 points in the TMJ region: superior, anterior, lateral, posterior and postero inferior to the condyle. In addition, all patients received laser application in the temporal muscle (anterior, middle and posterior), in the masseter (upper, middle and lower portion) and insertion of the medial pterygoid.
Study NCT03454581 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual Therapy (MT)
Description: Patients were submitted to MT at temporal, masseter and pterygoid medial from both sides, during 3 minutes each muscle group (Extraoral) and at masseter and lateral pterygoid (Intraoral) for 3 minutes, each total 21 minutes. MT on the TMJ region was performed for 1 minute and 3 repetitions during three times a week .
Study NCT03989557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin and clopidogrel/Ticagrelor
Description: The modification of aspirin and clopidogrel/ticagrelor maintenance doses based on a biomarker assays.
Study NCT03989557 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light transmittance aggregometry
Description: point-of-care method to assess platelet function by light transmittance aggregometry.
Study NCT03989557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin and clopidogrel/Ticagrelor
Description: maintenance dose of aspirin, clopidogrel and ticagrelor.
Study NCT01524510 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CT scan
Description: low dose radiation scan without contrast without and with MRA
Study NCT01524510 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alice PDx polygraphy
Description: Alice PDx polygraphy (Respironics)
Study NCT02335489 — intervention group
Intervention type: DEVICE
Intervention: Implantation with the commercially available Axium neurostimulator
Study NCT04190615 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: thromboelastometry test (TEM test)
Description: TEM test from the whole blood sample